Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-06-26 Sale |
2023-06-28 6:12 pm |
Avalo Therapeutics Inc. | AVTX | ARMISTICE CAPITAL LLC Armistice Capital Master Fund Ltd. Boyd Steven 10% Owner |
3,683,542 | $0.58881 | $2,168,897 | 765,828 (Indirect Direct) |
View |
| 2023-06-26 Purchase |
2023-06-27 4:10 pm |
Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner |
1,608,000 | $0.64066 | $1,030,179 | 0 (Indirect Direct) |
View |
| 2023-06-15 Purchase |
2023-06-20 4:04 pm |
Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner |
8,160 | $3.8779 | $31,644 | 1,608,000 (Indirect Direct) |
View |
| 2023-06-12 Purchase |
2023-06-14 4:14 pm |
Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner |
16,899 | $3.7653 | $63,629 | 1,599,840 (Indirect Direct) |
View |
| 2023-06-09 Purchase |
2023-06-13 4:41 pm |
Avalo Therapeutics Inc. | AVTX | Sullivan Christopher Ryan Chief Financial Officer |
511 | $3.42 | $1,748 | 1,262 (Direct) |
View |
| 2023-06-09 Purchase |
2023-06-13 4:39 pm |
Avalo Therapeutics Inc. | AVTX | NEIL GARRY ARTHUR CEO and Chairman of the Board |
4,000 | $3.42 | $13,680 | 13,220 (Direct) |
View |
| 2023-06-07 Purchase |
2023-06-09 4:24 pm |
Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner |
14,426 | $3.9124 | $56,440 | 1,582,941 (Indirect Direct) |
View |
| 2023-05-31 Purchase |
2023-06-02 4:22 pm |
Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner |
844 | $2.87 | $2,422 | 1,568,515 (Indirect Direct) |
View |
| 2023-05-25 Purchase |
2023-05-30 4:27 pm |
Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner |
2,671 | $2.7944 | $7,464 | 1,567,671 (Indirect Direct) |
View |
| 2023-05-24 Purchase |
2023-05-24 4:15 pm |
Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner |
9,000 | $2.9796 | $26,816 | 1,565,000 (Indirect Direct) |
View |
| 2023-05-18 Purchase |
2023-05-22 4:30 pm |
Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner |
26,621 | $3.3572 | $89,372 | 1,556,000 (Indirect Direct) |
View |
| 2023-05-12 Purchase |
2023-05-16 5:23 pm |
Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner |
4,379 | $2.5135 | $11,007 | 1,529,379 (Indirect Direct) |
View |
| 2023-05-04 Purchase |
2023-05-08 4:10 pm |
Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner |
25,000 | $2.7746 | $69,365 | 1,525,000 (Indirect Direct) |
View |
| 2023-04-25 Purchase |
2023-04-27 4:07 pm |
Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner |
7,500 | $2.9898 | $22,423 | 1,500,000 (Indirect Direct) |
View |
| 2023-04-20 Purchase |
2023-04-24 4:32 pm |
Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner |
17,500 | $3.0669 | $53,672 | 1,492,500 (Indirect Direct) |
View |
| 2023-04-17 Purchase |
2023-04-18 4:08 pm |
Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner |
25,000 | $2.955 | $73,874 | 1,475,000 (Indirect Direct) |
View |
| 2023-04-10 Purchase |
2023-04-11 4:51 pm |
Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner |
56,329 | $2.5301 | $142,516 | 1,450,000 (Indirect Direct) |
View |
| 2023-02-07 Purchase |
2023-02-09 4:32 pm |
Avalo Therapeutics Inc. | AVTX | ARMISTICE CAPITAL LLC Armistice Capital Master Fund Ltd. Boyd Steven 10% Owner |
450,000 | $0 | $0 | 4,899,370 (Indirect Direct) |
View |
| 2022-12-09 Purchase |
2022-12-12 4:22 pm |
Avalo Therapeutics Inc. | AVTX | NEIL GARRY ARTHUR CEO and Chairman of the Board |
2,083 | $4.42 | $9,207 | 9,220 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-12-20 Option Award |
2023-12-21 4:05 pm |
2024-12-20 2033-12-20 |
Avalo Therapeutics Inc. | AVTX | Persson Magnus Director |
3,334 | $0 | 3,334 (Direct) |
View |
| 2023-12-20 Option Award |
2023-12-21 4:04 pm |
2024-12-20 2033-12-20 |
Avalo Therapeutics Inc. | AVTX | Almenoff June Sherie Director |
3,334 | $0 | 3,334 (Direct) |
View |
| 2023-12-20 Option Award |
2023-12-21 4:03 pm |
2024-12-20 2033-12-20 |
Avalo Therapeutics Inc. | AVTX | KAPLAN GILLA Director |
3,334 | $0 | 3,334 (Direct) |
View |
| 2023-12-20 Option Award |
2023-12-21 4:01 pm |
2024-12-20 2033-12-20 |
Avalo Therapeutics Inc. | AVTX | Chan Mitchell Director |
3,334 | $0 | 3,334 (Direct) |
View |
| 2023-06-30 Option Award |
2023-07-05 4:07 pm |
2023-06-30 2033-06-30 |
Avalo Therapeutics Inc. | AVTX | Persson Magnus Director |
28,308 | $0 | 28,308 (Direct) |
View |
| 2023-06-30 Option Award |
2023-07-05 4:05 pm |
2023-06-30 2033-06-30 |
Avalo Therapeutics Inc. | AVTX | Almenoff June Sherie Director |
4,575 | $0 | 4,575 (Direct) |
View |
| 2023-05-15 Option Award |
2023-05-17 07:44 am |
2024-05-15 2033-05-15 |
Avalo Therapeutics Inc. | AVTX | Sullivan Christopher Ryan Chief Financial Officer |
40,000 | $0 | 40,000 (Direct) |
View |
| 2023-05-15 Option Award |
2023-05-17 07:43 am |
2024-05-15 2033-05-15 |
Avalo Therapeutics Inc. | AVTX | NEIL GARRY ARTHUR CEO and Chairman of the Board |
100,000 | $0 | 100,000 (Direct) |
View |
| 2023-03-31 Option Award |
2023-04-04 4:09 pm |
2023-03-31 2033-03-31 |
Avalo Therapeutics Inc. | AVTX | Almenoff June Sherie Director |
1,167 | $0 | 1,167 (Direct) |
View |
| 2023-03-31 Option Award |
2023-04-04 4:07 pm |
2023-03-31 2033-03-31 |
Avalo Therapeutics Inc. | AVTX | Persson Magnus Director |
7,222 | $0 | 7,222 (Direct) |
View |
| 2023-02-13 Option Award |
2023-02-15 4:19 pm |
N/A 2033-02-13 |
Avalo Therapeutics Inc. | AVTX | Sullivan Christopher Ryan Chief Financial Officer |
40,000 | $0 | 40,000 (Direct) |
View |
| 2023-02-13 Option Award |
2023-02-15 4:16 pm |
N/A 2033-02-13 |
Avalo Therapeutics Inc. | AVTX | NEIL GARRY ARTHUR CEO and Chairman of the Board |
100,000 | $0 | 100,000 (Direct) |
View |
| 2023-02-03 Acquisition |
2023-02-09 4:32 pm |
N/A N/A |
Avalo Therapeutics Inc. | AVTX | ARMISTICE CAPITAL LLC Armistice Capital Master Fund Ltd. Boyd Steven 10% Owner |
334 | $3.95 | 4,899,370 (Indirect) |
View |
| 2022-12-30 Option Award |
2023-01-03 4:13 pm |
2022-12-30 2032-12-30 |
Avalo Therapeutics Inc. | AVTX | Persson Magnus Director |
2,536 | $0 | 2,536 (Direct) |
View |
| 2022-12-30 Option Award |
2023-01-03 4:11 pm |
2022-12-30 2032-12-30 |
Avalo Therapeutics Inc. | AVTX | Almenoff June Sherie Director |
410 | $0 | 410 (Direct) |
View |
| 2022-10-05 Option Award |
2022-10-07 4:03 pm |
2023-10-05 2032-10-05 |
Avalo Therapeutics Inc. | AVTX | NEIL GARRY ARTHUR CEO and Chairman of the Board |
75,000 | $0 | 75,000 (Direct) |
View |
| 2022-10-05 Option Award |
2022-10-07 4:01 pm |
2023-10-05 2032-10-05 |
Avalo Therapeutics Inc. | AVTX | Sullivan Christopher Ryan Chief Financial Officer |
25,000 | $0 | 25,000 (Direct) |
View |
| 2022-09-30 Option Award |
2022-10-03 4:28 pm |
2022-09-30 2032-09-30 |
Avalo Therapeutics Inc. | AVTX | Almenoff June Sherie Director |
605 | $0 | 605 (Direct) |
View |
| 2022-09-30 Option Award |
2022-10-03 4:25 pm |
2022-09-30 2032-09-30 |
Avalo Therapeutics Inc. | AVTX | KAPLAN GILLA Director |
3,080 | $0 | 3,080 (Direct) |
View |
| 2022-09-30 Option Award |
2022-10-03 4:21 pm |
2022-09-30 2032-09-30 |
Avalo Therapeutics Inc. | AVTX | Persson Magnus Director |
3,747 | $0 | 3,747 (Direct) |
View |
| 2022-06-30 Option Award |
2022-07-05 5:34 pm |
2022-06-30 2032-06-30 |
Avalo Therapeutics Inc. | AVTX | Persson Magnus Director |
26,837 | $0 | 26,837 (Direct) |
View |